Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Newly Developed Compound Protects Heart Cells During and After Infarction

By BiotechDaily International staff writers
Posted on 18 Feb 2013
Using two recently developed diverse compounds, scientists have been able to show in animal models that suppressing a specific enzyme protects heart cells and neighboring tissue against the debilitating injury incurred by heart attacks. The compounds also protect against additional damage from restored blood flow after an attack, a process known as reperfusion.

The study, which was led by Dr. Philip LoGrasso, a professor and senior scientific director of discovery biology at the Florida campus of The Scripps Research Institute (TSRI; Jupiter, USA), was published in the February 8, 2013, print edition of the Journal of Biological Chemistry.

A myocardial infarction greatly restricts blood supply, starving heart cells and neighboring tissue of oxygen, which can cause enormous damage in comparatively little time—at times in just a few minutes. This decrease in oxygen, known as an ischemic cascade, results in a sudden crush of metabolic waste that damages cell membranes as well as the mitochondria.

Restoring blood flow adds considerably to the damage, unfortunately, a serious medical issue when it comes to treating major ischemic events such as stroke and heart attack. Reperfusion triggers generation of free radicals and reactive oxygen species that attack and damage cells, intensifying inflammation, signaling white blood cells to attack otherwise salvageable cells and maybe even stimulating potentially lethal cardiac arrhythmias.

The new study revealed that inhibiting the enzyme, c-jun-N-terminal kinase (JNK; pronounced junk), protected against ischemic/reperfusion injury in lab rodents, reducing the total volume of tissue death by as much as 34%. It also substantially decreased levels of reactive oxygen species and mitochondrial dysfunction.

In earlier studies, TSRI scientists discovered that JNK migrates to the mitochondria upon oxidative stress. That migration, combined with JNK activation, they found, is associated with a number of severe health issues, including liver damage, neuronal cell death, stroke, and heart attack. The peptide and small molecule inhibitor (SR3306), developed by Dr. LoGrasso and his colleagues, blocks those harmful effects, thereby reducing programmed cell death four-fold.

“This is the same story,” said Dr. LoGrasso. “These just happen to be heart cells, but we know that oxidative stress kills cells, and JNK inhibition protects against this stress. Blocking the translocation of JNK to the mitochondria is essential for stopping this killing cascade and may be an effective treatment for damage done to heart cells during an ischemic/reperfusion event.”

Moreover, according to Dr. LoGrasso, biomarkers that intensify during a heart attack decrease in the presence of JNK inhibition, a distinct indication that blocking JNK reduces the severity of the infarction.

Related Links:

The Scripps Research Institute




Channels

Genomics/Proteomics

view channel
Image: In mice, mitochondria (green) in healthy (left) and Mfn1-deficient heart muscle cells (center) are organized in a linear arrangement, but the organelles are enlarged and disorganized in Mfn2-deficient cells (right) (Photo courtesy of the Rockefeller Press).

Cell Biologists Find That Certain Mitochondrial Diseases Stem from Coenzyme Q10 Depletion

A team of German cell biologists has linked the development of certain mitochondrial-linked diseases to depletion of the organelles' pool of coenzyme Q10 brought about by mutation in the MFN2 gene, which... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.